CNS Lymphoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

CNS Lymphoma Epidemiology Forecast Report Coverage

Expert Market Research's “CNS Lymphoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of CNS Lymphoma. It projects the future incidence and prevalence rates of CNS lymphoma cases across various populations.  The study covers age, gender, and type as major determinants of the CNS lymphoma population. The report highlights patterns in the prevalence of CNS lymphoma over time and projects future trends based on multiple variables.

CNS Lymphoma Understanding: Disease Overview

Primary central nervous system lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma that originates in the brain, spinal cord, leptomeninges, or eyes and typically remains confined to the central nervous system. It mainly affects immunocompromised individuals, such as those with HIV/AIDS or transplant recipients, although immunocompetent individuals may also be affected. Symptoms include progressive neurological deficits, vision changes, and cognitive decline. Diagnosis relies on MRI, cerebrospinal fluid analysis, and brain biopsy to confirm the presence of malignant lymphocyte.

CNS Lymphoma Epidemiology Perspective

The CNS lymphoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the CNS lymphoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for CNS lymphoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Lauren R. Schaff et al., 2022, central nervous system lymphoma, also known as primary central nervous system lymphoma, accounts for 4% to 6% of all extranodal lymphomas and approximately 4% of newly diagnosed malignant brain tumors, reflecting a notable CNS malignancy burden within oncology.
• As per Kun-Wei Song et al., 2021, PCNSL diagnosis requires a high degree of clinical suspicion due to variable presentation, with nearly 70% of patients exhibiting focal neurological deficits, while others develop behavioral or cognitive changes, indicating diverse neurological symptom presentation patterns.
• According to Mikko Moisala et al., 2025, primary central nervous system lymphoma represents approximately 2.4%–3.0% of all brain tumors and less than 1% of lymphomas, highlighting its rarity within overall oncology and neuro-oncology disease burden globally.
• As per Mikko Moisala et al., 2025, the incidence of primary central nervous system lymphoma is around 0.47 per 100,000 population, with significantly higher occurrence among individuals aged over 60 years, indicating strong age-related susceptibility patterns, reflecting an evolving age-related lymphoma incidence trend.

Read more about this report - Request a Free Sample

Country-wise CNS Lymphoma Epidemiology

The CNS Lymphoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of CNS lymphoma varies significantly between countries due to differences in genetic factors, environmental exposures, and aging populations, reflecting a distinct regional lymphoma distribution pattern. According to Massive Bio, the incidence of primary CNS lymphoma globally ranges from 0.2 to 1.5 cases per 100,000 person-years, with a gradual increase attributed partly to an aging population. According to Memorial Sloan Kettering Cancer Center, approximately 1,500 cases are diagnosed annually in the United States, accounting for about 4% of nervous system tumors and 4–6% of non-Hodgkin lymphomas, with similar incidence trends observed across Europe, Japan, and India.

CNS Lymphoma: Treatment Overview

Primary central nervous system lymphoma (PCNSL) treatment primarily involves high-dose methotrexate-based chemotherapy, often combined with agents such as rituximab or cytarabine, reflecting established PCNSL treatment protocol patterns. Whole-brain radiation therapy is generally avoided in younger patients due to neurotoxicity risks but may be considered in refractory cases. Autologous stem cell transplantation is an option for eligible patients with recurrent disease. Corticosteroids may temporarily relieve symptoms but can complicate diagnostic accuracy if administered before biopsy.

Key Questions Answered

• What are the key findings of CNS lymphoma epidemiology in the 8 major markets?
• What will be the total number of patients with CNS lymphoma across the 8 major markets during the forecast period?
• What was the country-wise CNS lymphoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of CNS lymphoma patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of CNS lymphoma during the forecast period of 2026-2035?
• What are the currently available treatments for CNS lymphoma?
• What are the disease risks, signs, symptoms, and unmet needs of CNS lymphoma?

Scope of the CNS Lymphoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of CNS lymphoma based on several factors.
• CNS Lymphoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The CNS lymphoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hodgkin’s Lymphoma Treatment Market

T-cell Lymphoma Market